IL13 and Alzheimer disease: Tralokinumab (Adtralza, LEO Pharma A/S) is another human monoclonal IgG4 antibody licensed for use in the treatment of moderate-to-severe AD.26 It competitively blocks the binding of IL-13 to IL-13 Rα1 and IL-13 Rα2, restricting the connection with the IL-13 receptor and subsequent downstream signaling.27